3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Gastrointestinal
2
Endocrine
2
Conditions
Gastro-enteropancreatic neuroendocrine tumor
2
Neuroendocrine Tumors
1
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
pembrolizumab
604
Carboplatin
372
Paclitaxel
282
Cisplatin
267
Gemcitabine
252
Pemetrexed
193
Bevacizumab
190
Docetaxel
185
Nivolumab
181
Injections
167
Cyclophosphamide
147
atezolizumab
138
Fluorouracil
133
Capecitabine
133
Oxaliplatin
132
Dexamethasone
127
Fulvestrant
113
durvalumab
112
130-nm albumin-bound paclitaxel
110
fludarabine
101
Cetuximab
100
Leucovorin
97
Rituximab
94
venetoclax
90
Lenalidomide
83
enzalutamide
77
Prednisone
76
Azacitidine
74
Irinotecan
72
Ipilimumab
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
lanreotide
×
1 year
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled